What is the Prognosis for Patients with EML4-ALK Positive Cancers?
The prognosis for patients with EML4-ALK positive cancers has improved significantly with the advent of targeted therapies. Patients treated with ALK inhibitors typically experience a favorable response, with prolonged progression-free survival compared to traditional chemotherapy. However, resistance to ALK inhibitors can develop, necessitating ongoing research and the development of novel therapeutic strategies.
